FDA Among Regulatory Authorities Reeling From Brexit Bombshell
This article was originally published in The Rose Sheet
Executive Summary
Commissioner Robert Califf says FDA has no firm plan but will “react to whatever happens” following the UK’s momentous decision to leave the EU. The European Medicines Agency also is taking a wait-and-see approach, while regulated industries brace for potential compliance, R&D and IP challenges in Brexit’s aftermath.
You may also be interested in...
‘This Is The Time’ For Industry To Advocate TPP Approval – PCPC
The Trans-Pacific Partnership was high among the Personal Care Products Council’s priorities during its recent Lobby Day on Capitol Hill. The trade group’s Executive VP, Global Affairs Francine Lamoriello discussed the trade deal’s promise with the Rose Sheet while acknowledging the challenges it faces in the current political climate.
Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director
Nicole Verdun said children could participate in gene therapy clinical trials earlier if the necessary controls are in place.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.